[1]
|
McDonagh, T.A., Metra, M., Adamo, M., Gardner, R.S., Baumbach, A., Böhm, M., et al. (2021) 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal, 42, 3599-3726.
https://doi.org/10.1093/eurheartj/ehab368
|
[2]
|
胡盛寿, 高润霖, 刘力生, 朱曼璐, 王文, 王拥军, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(3): 209-220.
|
[3]
|
Teerlink, J.R. (2009) A Novel Approach to Improve Cardiac Performance: Cardiac Myosin Activators. Heart Fail Rev, 14, Article No. 289. https://doi.org/10.1007/s10741-009-9135-0
|
[4]
|
Burger, A.J., Horton, D.P., LeJemtel, T., Ghali, J.K., Torre, G., Dennish, G., et al. (2002) Effect of Nesiritide (B-Type Natriuretic Peptide) and Dobutamine on Ventricular Arrhythmias in the Treatment of Patients with Acutely Decompensated Congestive Heart Failure: The PRECEDENT Study. American Heart Journal, 144, 1102-1108.
https://doi.org/10.1067/mhj.2002.125620
|
[5]
|
Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G., Coats, A.J., et al. (2016) 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Kardiologia Polska, 74, 1037-1147.
https://doi.org/10.5603/KP.2016.0141
|
[6]
|
Overgaard, C.B. and Dzavik, V. (2008) Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease. Circulation, 118, 1047-1056. https://doi.org/10.1161/CIRCULATIONAHA.107.728840
|
[7]
|
Wang, X.C., Zhu, D.M. and Shan, Y.X. (2015) Dobutamine Therapy Is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decom-pensated Heart Failure: A Systematic Review and Meta-Analysis. American Journal of Cardiovascular Drugs, 15, 429-437. https://doi.org/10.1007/s40256-015-0134-3
|
[8]
|
Bristow, M.R. (2011) Treatment of Chronic Heart Fail-ure with Beta-Adrenergic Receptor Antagonists: A Convergence of Receptor Pharmacology and Clinical Cardiology. Circulation Research, 109, 1176-1194.
https://doi.org/10.1161/CIRCRESAHA.111.245092
|
[9]
|
Lohse, M.J., Engelhardt, S. and Eschenhagen, T. (2003) What Is the Role of Beta-Adrenergic Signaling in Heart Failure? Circulation Research, 93, 896-906. https://doi.org/10.1161/01.RES.0000102042.83024.CA
|
[10]
|
Pollesello, P., Parissis, J., Kivikko, M., and Harjola, V.P. (2016) Levosimendan Meta-Analyses: Is There a Pattern in the Effect on Mortality? International Journal of Cardi-olog, 209, 77-83. https://doi.org/10.1016/j.ijcard.2016.02.014
|
[11]
|
中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 洋地黄类药物临床应用中国专家共识[J]. 中华心血管病杂志, 2019, 47(11): 857-864.
|
[12]
|
Ziff, O.J. and Kotecha, D. (2016) Digoxin: The Good and the Bad. Trends in Cardiovascular Medicine, 26, 585-595.
https://doi.org/10.1016/j.tcm.2016.03.011
|
[13]
|
Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G.F., Coats, A.J.S., et al. (2016) 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic heart Failure of the European Society of Cardiology (ESC). Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. Euro-pean Journal of Heart Failure, 18, 891-975.
https://doi.org/10.1002/ejhf.592
|
[14]
|
Adams Jr., K.F., Butler, J., Patterson, J.H., Gattis Stough, W., Bauman, J.L., van Veldhuisen, D.J., et al. (2016) Dose Response Characterization of the Association of Serum Digoxin Concentration with Mortality Outcomes in the Digitalis Investigation Group Trial. European Journal of Heart Failure, 18, 1072-1081. https://doi.org/10.1002/ejhf.584
|
[15]
|
Vamos, M., Erath, J.W. and Hohnloser, S.H. (2015) Digoxin-Associated Mortality: A Systematic Review and Meta-Analysis of the Literature. European Heart Journal, 36, 1831-1838. https://doi.org/10.1093/eurheartj/ehv143
|
[16]
|
Bavishi, C., Khan, A.R. and Ather, S. (2015) Digoxin in Patients with Atrial Fibrillation and Heart Failure: A Meta-Analysis. International Journal of Cardiology, 188, 99-101. https://doi.org/10.1016/j.ijcard.2015.04.031
|
[17]
|
Van Gelder, I.C., Groenveld, H.F., Crijns, H.J., Tuininga, Y.S., Tijssen, J.G., Alings, A.M., et al. (2010) Lenient versus Strict Rate Control in Patients with Atrial Fibrillation. New Eng-land Journal of Medicine, 362, 1363-1373.
https://doi.org/10.1056/NEJMoa1001337
|
[18]
|
Francis, G.S., Bartos, J.A. and Adatya, S. (2014) Inotropes. Journal of the American College of Cardiology, 63, 2069-2078. https://doi.org/10.1016/j.jacc.2014.01.016
|
[19]
|
Lewis, T.C., Aberle, C., Altshuler, D., Piper, G.L. and Papadopoulos, J. (2019) Comparative Effectiveness and Safety between Milri-none or Dobutamine as Initial Inotrope Therapy in Cardiogenic Shock. Journal of Cardiovascular Pharmacology and Therapeutics, 24, 130-138. https://doi.org/10.1177/1074248418797357
|
[20]
|
Cuffe, M.S., Califf, R.M., Adams Jr., K.F., Benza, R., Bourge, R., Colucci, W.S., et al. (2002) Short-Term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure: A Randomized Controlled Trial. JAMA, 287, 1541-1547.
https://doi.org/10.1001/jama.287.12.1541
|
[21]
|
Kersten, J.R., Montgomery, M.W., Pagel, P.S. and Warltier, D.C. (2000) Levosimendan, a New Positive Inotropic Drug, Decreases Myocardial Infarct Size via Activation of K(ATP) Channels. Anesthesia & Analgesia, 90, 5-11.
https://doi.org/10.1097/00000539-200001000-00003
|
[22]
|
Papp, Z., Édes, I., Fruhwald, S., De Hert, S.G., Sal-menperä, M., Leppikangas, H., et al. (2012) Levosimendan: Molecular Mechanisms and Clinical Implications: Consensus of Experts on the Mechanisms of Action of Levosimendan. International Journal of Cardiology, 159, 82-87. https://doi.org/10.1016/j.ijcard.2011.07.022
|
[23]
|
中国医师协会心血管内科医师分会, 中国心血管健康联盟, 心肌梗死后心力衰竭防治专家共识工作组. 2020心肌梗死后心力衰竭防治专家共识[J]. 中国循环杂志, 2020, 35(12): 1166-1180.
|
[24]
|
Shen, Y.T., Malik, F.I., Zhao, X., Depre, C., Dhar, S.K., Abarzúa, P., et al. (2010) Improve-ment of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs with Systolic Heart Failure. Circulation: Heart Failure, 3, 522-527.
https://doi.org/10.1161/CIRCHEARTFAILURE.109.930321
|
[25]
|
Teerlink, J.R., Clarke, C.P., Saikali, K.G., Lee, J.H., Chen, M.M., Escandon, R.D., et al. (2011) Dose-Dependent Augmentation of Cardiac Systolic Function with the Selective Cardiac Myosin Activator, Omecamtiv Mecarbil: A First-in-Man Study. Lancet, 378, 667-675. https://doi.org/10.1016/S0140-6736(11)61219-1
|
[26]
|
Cleland, J.G., Teerlink, J.R., Senior, R., Nifontov, E.M., Mc Murray, J.J., Lang, C.C., et al. (2011) The Effects of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Cardiac Function in Systolic Heart Failure: A Double-Blind, Placebo-Controlled, Crossover, Dose-Ranging Phase 2 Trial. Lancet, 378, 676-683.
https://doi.org/10.1016/S0140-6736(11)61126-4
|
[27]
|
Teerlink, J.R., Felker, G.M., McMurray, J.J.V., Ponikowski, P., Metra, M., Filippatos, G.S., et al. (2016) Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. Journal of the American College of Cardiology, 67, 1444-1455. https://doi.org/10.1016/j.jacc.2016.01.031
|
[28]
|
Teerlink, J.R., Felker, G.M., McMurray, J.J., Solomon, S.D., Ad-ams Jr., K.F., Cleland, J.G., et al. (2016) Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): A Phase 2, Pharmacokinetic, Randomised, Placebo-Controlled Trial. Lancet, 388, 2895-2903. https://doi.org/10.1016/S0140-6736(16)32049-9
|
[29]
|
Teerlink, J.R., Diaz, R., Felker, G.M., McMurray, J.J.V., Metra, M., Solomon, S.D., et al. (2021) Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. New England Journal of Medicine, 384, 105-116.
https://doi.org/10.1056/NEJMoa2025797
|
[30]
|
Lewis, G.D., Docherty, K.F., Voors, A.A., Cohen-Solal, A., Metra, M., Whellan, D.J., et al. (2022) Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. Circulation: Heart Failure, 15, e008970. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008970
|